Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation

To observe and evaluate the efficacy and safety of neoadjuvant long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib Mesylate in the treatment of locally advanced rectal cancer and low-lying rectal cancer with sphincter-preservation demand.

NCT Number	NCT07687433
Lead Sponsor	Harbin Medical University
Conditions	Rectal Cancer Patients
Enrollment	43 participants
Start Date	2026-05-29
Primary Completion	2028-05-29 (estimated)
Study Completion	2029-05-29 (estimated)
Updated on ClinicalTrials.gov	2026-07-07